Imagine trading 365 injections a year for just 52.
That's not a typo.
That's the new reality for diabetics in India.
Meet Awiqli — the world's first once-a-week basal insulin.
Launched by Novo Nordisk on July 9, 2026.
India is now the 7th country to get it.
For decades, insulin-dependent diabetics lived by a brutal clock.
Same time. Every single day. No exceptions.
Miss a dose, and blood sugar spirals.
Now?
One shot.
Once a week.
That's it.
The drug is called insulin icodec.
It's engineered to stay active in the bloodstream far longer than regular insulin — releasing steadily over seven days instead of one.
Approved for:
Same control. Way fewer needles.
You'd expect a "world's first" therapy to cost a fortune.
It doesn't.
👉 A weekly dose of 70 units costs just ₹261 — about $3.
👉 A 1mL pen: ₹2,611
👉 A 3mL pen: ₹7,833
Let that sink in.
Cutting-edge science, priced for everyday India.
India carries one of the world's largest diabetic populations.
Millions skip doses simply because daily injections are exhausting — physically, mentally, logistically.
Fewer injections could mean better adherence.
Better adherence could mean fewer complications.
Fewer complications could mean lives genuinely changed.
This isn't just a new drug.
It's a shift in what "managing a chronic disease" even means.
From a daily burden…
to a weekly checkbox.
For millions of Indians, that difference might just be everything.
That's all for now!
